|
|
|||||||||
Basic Science Investigation |
1 Department of Nuclear Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea; 2 Cardiovascular Center, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea; and 3 Cardiology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Correspondence: For correspondence contact: Kyung-Han Lee, MD, Department of Nuclear Medicine, Samsung Medical Center, 50 Ilwondong, Kangnamgu, Seoul, Korea 135-710. E-mail: khleenm{at}yahoo.co.kr
Adenoviral Na/I symporter (NIS) gene transfer has emerged as a promising method for myocardial gene imaging but concern over possible perturbation of cardiac function persists. In this study, we addressed this issue with cultured cardiac cells and serial echocardiography, creatine kinase (CK) measurements, and histologic examination of rats intramyocardially injected with an adenovirus that expresses both NIS and enhanced green fluorescent protein (EGFP) (Ad.EGFP.NIS) or a control virus (Ad.EGFP). Methods: H9C2 cardiac myoblasts differentiated into cardiomyocytes were evaluated for the effect of Ad.EGFP.NIS and Ad.EGFP infection on viable cell number and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Rats injected intramyocardially with 3 x 108 plaque-forming units of Ad.EGFP.NIS (n = 9) or Ad.EGFP (n = 8) underwent serial echocardiographic measurements of heart rate, left ventricular (LV) dimensions, ejection fraction (EF), and fractional shortening (FS) on the day before and on days 4 and 9 after gene transfer. Five Ad.EGFP.NIS rats also underwent repeated 123I imaging from which ratios of cardiac to mediastinal counts (C/M ratios) were obtained. Separate rats underwent serial measurements of serum CK, myocardial myeloperoxidase assays, and microscopic assessment of inflammation. Results: Cultured cardiac cells showed no change in cell viability or proliferation at 4 and 9 d after Ad.EGFP.NIS or Ad.EGFP infection compared with controls. 123I scintigraphy demonstrated high cardiac radiouptake at Ad.EGFP.NIS injection sites by days 2 and 4 (C/M ratios, 5.0 ± 0.6 and 5.1 ± 1.0, respectively), followed by a complete loss of uptake by day 9 (C/M ratio, 1.4 ± 0.0). Serial echocardiography revealed no difference in heart rate, LV dimensions, or functional parameters between Ad.EGFP.NIS and Ad.EGFP groups at any given time. Mild reductions in LVEF and LVFS by day 9 compared with baseline were similar for both Ad.EGFP (88.2% ± 6.4% vs. 79.6% ± 5.0% for LVEF and 0.55 ± 0.10 vs. 0.44 ± 0.05 for LVFS) and Ad.EGFP.NIS groups (88.0% ± 5.4% vs. 78.7% ± 4.6% for LVEF and 0.54 ± 0.09 vs. 0.42 ± 0.05 for LVFS). Serial serum CK and myocardial myeloperoxidase activities were not elevated in either group, in contrast to substantial increases found after ischemiareperfusion injury. Histology revealed similar mild inflammatory cell infiltration restricted to the injection site for both groups. Conclusion: The results of this study demonstrate that myocardial NIS gene imaging does not cause significant myocardial injury or perturbed cardiac function, other than mild effects likely due to adenoviral vectorassociated host response. Thus, this practical and convenient reporter gene strategy can be used safely for noninvasive myocardial gene imaging in living subjects.
Key Words: reporter gene gene therapy myocardium radioiodide scintigraphy
Related articles in JNM:
This article has been cited by other articles:
![]() |
D. Ricci, A. A. Mennander, L. D. Pham, V. P. Rao, N. Miyagi, G. W. Byrne, S. J. Russell, and C. G.A. McGregor Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 32 - 39. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |